Dark Forest Capital Management LP Takes Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Dark Forest Capital Management LP bought a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 6,610 shares of the company's stock, valued at approximately $532,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC lifted its position in PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after buying an additional 145 shares in the last quarter. Naviter Wealth LLC raised its position in shares of PROCEPT BioRobotics by 6.0% in the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company's stock valued at $249,000 after acquiring an additional 176 shares during the period. Amundi raised its position in shares of PROCEPT BioRobotics by 0.9% in the 4th quarter. Amundi now owns 20,143 shares of the company's stock valued at $1,742,000 after acquiring an additional 183 shares during the period. Arizona State Retirement System raised its position in shares of PROCEPT BioRobotics by 1.5% in the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock valued at $1,150,000 after acquiring an additional 218 shares during the period. Finally, KRS Capital Management LLC raised its holdings in PROCEPT BioRobotics by 0.5% during the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company's stock worth $3,741,000 after buying an additional 225 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.

Insider Transactions at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 733 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Reza Zadno sold 5,475 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,455 shares of company stock valued at $368,322. Company insiders own 17.40% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on PRCT. Morgan Stanley dropped their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Bank of America lowered their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Finally, Truist Financial lowered their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics has a consensus rating of "Moderate Buy" and an average price target of $90.00.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT traded down $0.68 during trading on Thursday, reaching $53.30. The company's stock had a trading volume of 216,701 shares, compared to its average volume of 810,566. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -27.36 and a beta of 1.09. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81. The firm has a 50 day moving average price of $57.13 and a 200 day moving average price of $73.61.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The firm had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. The business's revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, equities analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).